Suppression of Thromboxane A2 but Not of Systemic Prostacyclin by Controlled-Release Aspirin

New England Journal of Medicine

Volumn 325, Issue 16, 1991, Pages 1137-1141

  Clarke, Robert J ^a   Mayo, Gail ^a   Price, Patricia ^a   Fitzgerald, Garret A ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; THROMBOXANE A2; BRADYKININ; DELAYED ACTION PREPARATIONS; SALICYLIC ACID DERIVATIVE;

ADULT; ARTICLE; BLOOD CLOT LYSIS; DRUG COMPARISON; DRUG EFFECT; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; THROMBOCYTE; ADOLESCENT; BIOSYNTHESIS; BLOOD; CHEMICAL PHENOMENA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; METABOLISM; RANDOMIZED CONTROLLED TRIAL; URINE;

ADOLESCENT; ADULT; ASPIRIN; BLOOD PLATELETS; BRADYKININ; COMPARATIVE STUDY; DELAYED-ACTION PREPARATIONS; DEPRESSION, CHEMICAL; DRUG ADMINISTRATION SCHEDULE; EPOPROSTENOL; HUMAN; MALE; MIDDLE AGE; SALICYLATES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOXANE A2;

EID: 0025925211     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199110173251605     Document Type: Article

References (43)

1. Lewis H.D. Jr., Davis J.W., Archibald D.G., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309:396-403
2. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-30
3. Hennekens C.H., Buring J.E., Sandercock P., Collins R., Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80:749-56
4. Reilly I.A.G., FitzGerald G.A. Aspirin in cardiovascular disease. Drugs 1988; 35:154-76
5. Hamberg M., Samuelsson B. Prostaglandin endoperoxides, novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci U S A 1974; 71:3400-4
6. DeWitt D.L., Smith W.L. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci U S A 1988; 85:1412-6
7. Funk C., Funk L.B., Kennedy M., Pong A., FitzGerald G.A. Human platelet/erythroleukemia cell PGG/H synthase: cDNA cloning, expression, mutagenesis and gene chromosomal assignment. FASEB J 1991; 5:230412
8. Vane J.R., Änggård E.E., Botting R.M. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323:27-36
9. Moneada S., Gryglewski R., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263:663-5
10. Patrignani P., Filabozzi P., Patrono C. Selective, cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366-72
11. Hanley S.P., Bevan J., Cockbill S.R., Heptinstall S. A regimen for low-dose aspirin? BMJ 1982; 285:1299-302
12. Ciabattoni G., Boss A.H., Daffonchio L., et al. Radioimmunoassay measurement of 2,3-dinor metabolites of prostacyclin and thromboxane in human urine. Adv Prostaglandin Thromboxane Leukotriene Res 1987; 17B:598602
13. Braden G., Knapp H.R., FitzGerald G.A. Suppression of eicosanoid formation during coronary angioplasty by fish oil and aspirin. Circulation 1991; 84:679-85
14. Rowland M., Riegelman S., Harris P.A., Sholkoff S.B. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sei 1972; 61:379-85
15. Ritter J.M., Cockcroft J.R., Doktor H.S., Beacham J., Barrow S.E. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. Br J Clin Pharmacol 1989; 28:573-9
16. Pedersen A.K., FitzGerald G.A. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311:120611
17. De Caterina R., Giannessi D., Boem A., et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost 1985; 54:528-32
18. Jakubowski J.A., Stampfer M.J., Vaillancourt R., Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985; 60:635-42
19. Baenziger N.L., Becherer P.R., Majerus P.W. Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts. Cell 1979; 16:967-74
20. Heavey D.J., Barrow S.E., Hickling N.E., Ritter J.M. Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man. Nature 1985; 318:186-8
21. FitzGerald G.A., Smith B., Pedersen A.K., Brash A.R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310:1065-8
22. Lawson J.L., Brash A.R., Doran J., FitzGerald G.A. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography — negative-ion chemical ionization mass spectrometry. Anal Biochem 1985; 150:463-70
23. Knapp H.R., FitzGerald G.A. The antihypertensive effects of fish oil: a controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med 1989; 320:1037-43
24. Pedersen A.K., FitzGerald G.A. Preparation and analysis of deuterium labeled aspirin: application to pharmacokinetic studies. J Pharm Sci 1985; 74:188-92
25. Mielke C.H. Influence of aspirin on platelets and the bleeding time. Am J Med 1983; 74:Suppl 6A:72-78
26. FitzGerald G.A., Lupinetti M., Charman S.A., Charman W.N. Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for THROMBOXANE A2. J Pharmacol ExpTher (in press)
27. Siegel S., Castellan N.J. Jr. Nonparametric statistics for the behavioral sciences. 2nd ed. New York: McGraw-Hill, 1988
28. Lorenz R.L., Boehlig B., Uedelhoven W.M., Weber P.C. Superior antiplatelet action of alternate day pulsed dosing versus split dose administration of aspirin. Am J Cardiol 1989; 64:1185-8
29. Burch J.W., Stanford N., Majerus P.W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61:314-9
30. Demers L.M., Budin R.E., Shaikh B.S. The effects of aspirin on megakaryocyte prostaglandin production. Proc Soc Exp Biol Med 1980; 163:24-9
31. Walenga R.W., Miller J.L., Stuart M.J. Recovery of megakaryocyte thromboxane production in vitro after aspirin inhibition. Biochem Biophys Res Commun 1984; 119:982-8
32. Nowak J., FitzGerald G.A. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest 1989; 83:3805
33. Fitzgerald D.J., Roy L., Catella F., FitzGerald G.A. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983-9
34. Cannon P.J. Prostaglandins in congestive heart failure and the effects of nonsteroidal anti-inflammatory drugs. Am J Med 1986; 81:Suppl 2B:12332
35. Patrono C., Pierucci A. Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease. Am J Med 1986; 81:Suppl 2B:71-83
36. Sieben C.J., Bochner F., Imhoff D.M., et al. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 1983; 33:367-74
37. Weksler B.B., Pett S.B., Alonso D., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308:800-5
38. FitzGerald G.A., Oates J.A., Hawiger J., Maas R.L., Roberts L.J., Brash A.R. Endogenous synthesis of prostacyclin and thromboxane and platelet function during chronic aspirin administration in man. J Clin Invest 1983; 71:676-88
39. FitzGerald G.A., Oates J.A. Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35:633-40
40. Cerletti C., Gambino M.C., Garattini S., de Gaetano G. Biochemical selectivity of oral versus intravenous aspirin in rats: inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels. J Clin Invest 1986; 78:323-6
41. Uzan S., Beaufils M., Breart G., Bazin B., Capitant C., Paris J. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991; 337:1427-31
42. Fitzgerald D.J., Entman S.S., Mulloy K., FitzGerald G.A. Decreased prostacyclin biosynthesis preceding the clinical manifestation of ppregnancy-induced hypertension. Circulation 1987; 75:956-63
43. Benigni A., Gregorini G., Frusca T., et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for ppregnancy-induced hypertension. N Engl J Med 1989; 321:357-62